Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | PAM | P19021 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6448229 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL989180 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL5395399 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Ethyl Tetradecanoate SCHEMBL8330964 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL1682182 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL173634 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL2213929 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL787652 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL3028566 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL543614 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115461334-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-116425722-A | Substituted bipyridone-aryl (hetero) ring compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-110383518-B | Organic light-emitting element | 株式会社LG化学 | 2023-05-09 | — | — | CN | disclosed |
| CN-115703792-A | Tricyclic derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115461334-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-1186607-B1 | OPTICALLY ACTIVE PYRROLOPYRIDAZINE COMPOUNDS | SANKYO CO (JP) | 2003-05-21 | — | — | EP | disclosed |
| CN-1419547-A | Compounds with Thrombopoietin Receptor Agonism | SHIONOGI & CO (JP) | 2003-05-21 | — | — | CN | disclosed |
| EP-1254907-A1 | PYRROLOPYRIDAZINE COMPOUND | Sankyo Company, Limited (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1253142-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020156079-A1 | Optically active pyrrolopyridazine derivatives | SANKYO COMPANY, LIMITED (JP) | 2002-10-24 | — | — | US | disclosed |
| EP-1186607-A1 | OPTICALLY ACTIVE PYRROLOPYRIDAZINE COMPOUNDS | Sankyo Company, Limited (JP) | 2002-03-13 | — | — | EP | disclosed |
| EP-0713131-B1 | Silver halide photographic material | FUJI PHOTO FILM CO LTD (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5688630-A | CONTAINING A HYDRAZIDE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0713131-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1996-05-22 | — | — | EP | disclosed |
| US-5091549-A | SYNTHESIS OF D-MYOINOSITOL-1-PHOSPHATE | THE YOKOHAMA RUBBER COMPANY, LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156079-A1 | Optically active pyrrolopyridazine derivatives | GIPR, HRH2, PGA5 | ESR1 3738/4885DGKA 3018/4885PAM 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.